EBR Systems (ASX:EBR): Wireless Cardiac Pacing Technology and Manufacturing Progress Update

Sonal Goyal

15 September 2026 03:29 AM AEST

EBR Systems (ASX:EBR): Wireless Cardiac Pacing Technology and Manufacturing Progress Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

EBR Systems (ASX:EBR) develops wireless cardiac pacing technology.
The company’s WiSE System is designed for cardiac rhythm disease applications.
EBR progressed regulatory and Manufacturing activities during 2026.
The company is expanding manufacturing capabilities through its Santa Clara facility.
Regulatory approvals, production capacity and commercial adoption remain key areas to monitor.

EBR Systems (ASX:EBR) is a medical device company focused on wireless cardiac pacing technology. The company is developing the WiSE System, a leadless approach designed to support cardiac resynchronisation therapy, while progressing manufacturing and regulatory milestones.

Company Overview

EBR Systems is a United States incorporated company headquartered in Santa Clara, California, and listed on the ASX in November 2021.

The company focuses on cardiac rhythm disease and develops stimulation technology designed to operate without traditional pacing leads.

The WiSE System is EBR’s wireless cardiac pacing platform, designed to provide stimulation through an alternative approach to conventional lead-based systems.

The company’s activities include medical device development, regulatory processes and manufacturing expansion.

The company’s official information highlights its focus on developing wireless pacing technology for cardiac applications.

Regulatory and Manufacturing Progress

In September 2026, EBR reported that the United States Food and Drug Administration completed its review of a previously disclosed Cybersecurity incident.

The company stated that no immediate field corrective action or recall of the WiSE System was required.

EBR also progressed manufacturing activities at its Santa Clara facility, including installation of automated assembly equipment.

Commercial Development

The company is focused on expanding production capability and supporting future commercial rollout of the WiSE System.

Manufacturing automation is intended to improve production capacity following relevant approvals.

Future progress depends on regulatory milestones, manufacturing execution and adoption of the technology.

Risks and Considerations

Medical device companies face risks associated with regulatory approvals, clinical adoption and reimbursement conditions.

EBR operates a focused product platform, making progress dependent on the successful development and commercialisation of the WiSE System.

The company remains exposed to funding requirements while continuing product development and expansion activities.

Key Insights

EBR Systems (ASX:EBR) is advancing a specialised wireless cardiac pacing technology platform. Future progress will depend on regulatory outcomes, manufacturing scale-up, commercial adoption and effective execution of its development strategy.

FAQs

Q:What is the ASX ticker for EBR Systems?

A:EBR Systems trades under (ASX:EBR).

Q:What does EBR Systems develop?

A:The company develops wireless cardiac pacing technology.

Q:What is the WiSE System?

A:The WiSE System is EBR Systems’ wireless cardiac pacing platform.

Q:Where is EBR Systems headquartered?

A:The company is headquartered in Santa Clara, California.

Q:What factors are important for EBR Systems?

A:Regulatory progress, manufacturing, adoption and execution are key factors to monitor.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.